The correlation between immune subtypes and consensus molecular subtypes in colorectal cancer identifies novel tumour microenvironment profiles, with prognostic and therapeutic implications by Soldevilla, B. et al.
European Journal of Cancer 123 (2019) 118e129Available online at www.sciencedirect.com
ScienceDirect
journal homepage: www.ejcancer.comOriginal ResearchThe correlation between immune subtypes and consensus
molecular subtypes in colorectal cancer identifies novel
tumour microenvironment profiles, with prognostic and
therapeutic implicationsB. Soldevilla a,b,1, C. Carretero-Puche a,b,1, G. Gomez-Lopez c,
F. Al-Shahrour c, M.C. Riesco a,d, B. Gil-Calderon a,b,
L. Alvarez-Vallina e,f,g, P. Espinosa-Olarte a,d, G. Gomez-Esteves a,b,
B. Rubio-Cuesta a,b, J. Sarmentero a,b, A. La Salvia a,d,
R. Garcia-Carbonero a,d,h,*a Laboratorio de Oncologı´a Clı´nico-Traslacional, Unidad de Investigacio´n en Tumores Digestivos, Instituto de Investigacio´n
Iþ12, Hospital 12 de Octubre, 28041, Madrid, Spain
b Centro Nacional de Investigacio´n Oncolo´gica (CNIO), 28029, Madrid, Spain
c Bioinformatics Unit, Centro Nacional de Investigacio´n Oncolo´gica (CNIO), 28029, Madrid, Spain
d Oncology Department, Hospital Universitario Doce de Octubre, Instituto de Investigacio´n Sanitaria Hospital 12 de Octubre
(imas12), UCM, CNIO, CIBERONC, Madrid, Spain
e Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, 28041, Madrid,
Spain
f Immuno-Oncology and Immunotherapy Group, Instituto de Investigacio´n Sanitaria 12 de Octubre (iþ12), 28041, Madrid,
Spain
g Immunotherapy and Cell Engineering Laboratory, Department of Engineering, Aarhus University, 8000, C Aarhus, Denmark
h Complutense University of Madrid, Madrid, SpainReceived 4 July 2019; received in revised form 29 August 2019; accepted 16 September 2019
Available online 1 November 2019KEYWORDS
Colorectal cancer;
Immune subtypes;
Consensus molecular
subtypes;* Corresponding author: Medical Onc
Spain.Fax: þ34 91 4603310
E-mail address: rgcarbonero@gmail
1 These authors contributed equally t
https://doi.org/10.1016/j.ejca.2019.09.00
0959-8049/ª 2019 The Author(s). Pu
creativecommons.org/licenses/by-nc-nd/Abstract Background: Solid tumour growth is the consequence of a complex interplay be-
tween cancer cells and their microenvironment. Recently, a new global transcriptomic immune
classification of solid tumours has identified six immune subtypes (ISs) (C1eC6). Our aim was
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microenviroment;
ImmunotherapyMethods: Clinical and molecular information, including CMSs and ISs, were obtained from
The Cancer Genome Atlas (TCGA) (N Z 625). Immune cell populations, differential gene
expression and gene set enrichment analysis were performed to characterise ISs in the global
CRC population by using CMSs.
Results: Only 5 ISs were identified in CRC, predominantly C1 wound healing (77%) and C2
IFN-g dominant (17%). CMS1 showed the highest proportion of C2 (53%), whereas C1 was
particularly dominant in CMS2 (91%). CMS3 had the highest representation of C3 inflamma-
tory (7%) and C4 lymphocyte depleted ISs (4%), whereas all C6 TGF-b dominant cases belonged
to CMS4 (2.3%). Prognostic relevance of ISs in CRC substantially differed from that reported
for the global TCGA, and ISs had a greater ability to stratify the prognosis of CRC patients
than CMS classification. C2 had higher densities of CD8, CD4 activated, follicular helper T
cells, regulatory T cells and neutrophils and the highest M1/M2 polarisation. C2 had a height-
ened activation of pathways related to the immune system, apoptosis and DNA repair, mTOR
signalling and oxidative phosphorylation, whereas C1 was more dependent of metabolic path-
ways.
Conclusions: The correlation of IS and CMS allows a more precise categorisation of patients
with relevant clinical and biological implications, which may be valuable tools to improve
tailored therapeutic interventions in CRC patients.
ª 2019 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Colorectal cancer (CRC) is one of the leading causes of
cancer-related death. CRC management is primarily
based on tumour location and extent of disease, with a
very limited repertoire of molecular biomarkers to guide
personalised patient care. CRC is however a heteroge-
neous disease with widely variable clinical outcomes,
both in terms of prognosis and drug response. Tumour
diversity is also reflected at the molecular level, and
molecular classifications of CRC have substantially
evolved in recent years.
At the genomic level, two major groups can be
identified as follows: i) hypermutated (w15% of
CRCs), often with microsatellite instability (MSI)
and are associated with a rich immune cell infiltra-
tion, a favourable prognosis in early stages and a
particular susceptibility to immune checkpoint inhi-
bition in advanced disease and ii) non-hypermutated
(w85%), that generally present chromosomal insta-
bility (CIN), and are associated with a worse prog-
nosis and a poor response to immunotherapy.
However, the only genomic events well established to
guide standard therapy in the clinic are RAS muta-
tions, to exclude epidermal growth factor receptor
(EGFR)-targeted therapy, and MSI, to select pa-
tients for treatment with immune checkpoint
inhibitors.
But cancer initiation and progression are the conse-
quence of a complex interplay between tumour cells and
their microenvironment. In this regard, transcriptomic
classifications have improved the biological characteri-
sation of CRC, as they encompass not only the tumour
cells but also the immune and stromal components ofcancer [1e6]. In 2015, the international CRC Subtyping
Consortium proposed a unified transcriptomic classifi-
cation that identified four biologically distinct consensus
molecular subtypes (CMSs) [7]: CMS1 (MSI immune
subtype [IS], 14%), characterised by BRAF muta-
tioneenriched, hypermutated and hypermethylated tu-
mours, with a strong immune activation; CMS2
(canonical subtype, 37%), commonly CIN tumours with
upregulation of WNT and MYC signalling; CMS3
(metabolic subtype, 13%), encompasses epithelial tu-
mours with metabolic deregulation, enriched in KRAS
mutations; and CMS4 (mesenchymal subtype, 23%),
defined by a strong activation of
epithelialemesenchymal transition, angiogenesis and
stemness pathways; this is the CMS with the worst
outcome [7]. The CMS is the most robust classification
currently available to stratify CRC. However, trained on
disease biology rather than on clinical outcome, it has
been associated with prognosis but its predictive value
remains to be properly addressed [8e10].
In addition to focussing on tumour microenviron-
ment, Becht et al., [11] analysed the composition and
functional orientation of the immune and stromal
components of CRC by CMS. In this study, CMS2 and
CMS3 were found to be immunologically ‘cold’, as they
were devoid of lymphoid and myeloid infiltration, and
had poor expression of major histocompatibility com-
plex(MHC1) genes. On the contrary, CMS1, associated
with a good prognosis, presented overexpression of
genes specific to cytotoxic lymphocytes, and CMS4,
associated with a poor prognosis, overexpressed
markers of lymphocytes and monocytes and signatures
characteristic of angiogenesis, inflammation and
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density.
Recently, Thorsson et al [12]. have developed a new
global immune classification of solid tumours based on
the transcriptomic profiles of over 10,000 patients from
all 33 non-haematological The Cancer Genome Atlas
(TCGA) cancer types. They identified 6 distinct im-
mune subtypes (ISs). The wound healing (C1) showed
an elevated expression of angiogenic genes, a high
proliferation rate and a low Th1/Th2 ratio related to
the adaptive immune infiltrate. The IFN-g dominant
(C2) presented a high proliferation rate, the highest
intratumoral heterogeneity, macrophages M1/M2
polarisation and CD8 T cell population and the
greatest T-cell receptor (TCR) diversity. The inflam-
matory (C3) was defined by elevated Th17 and Th1
genes, low to moderate proliferation, lower levels of
aneuploidy, higher somatic copy-number alterations
and the most favourable prognosis. The lymphocyte
depleted (C4) presented moderate cell proliferation and
intratumoral heterogeneity, and a prominent macro-
phage signature with Th1 suppressed and a high M2
response; consistent with these features, it was associ-
ated with a poor outcome. The immunologically quiet40.0 
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Fig. 1. Distribution of colorectal cancer patients according to consensus
interconnectivity between CMSs (N Z 545) and ISs (N Z 489). The
CMS3 (N Z 70) and CMS4 (N Z 134)), the Y-axis shows the ISs (w
(NZ 15), lymphocyte depleted (NZ 7) and TGF-b dominant (NZ 3)) a
specific group.(C5) displayed the lowest lymphocyte and highest
macrophage responses, dominated by M2, and had low
rates of proliferation and heterogeneity. Finally, the
TGF-b dominant (C6) was a small group of mixed tu-
mours with the highest TGF-b signature and a high
lymphocytic infiltrate with a balanced Th1:Th2 ratio.
Together with C4, C6 was associated with the worst
prognosis [12].
This recent immune classification, thus, spans across
traditional cancer classifications based on anatomical
site of origin and suggests that certain therapeutic
approaches may be considered regardless of tumour
location or histology. However, individual tumour
types varied substantially in their proportion of ISs
and in their prognostic impact. In this context, the
purpose of our study was to specifically characterise,
from a clinical and molecular perspective, the ISs in a
large cohort of CRC patients. We aimed to explore the
distribution by IS of relevant clinical and pathological
features, genomic and transcriptomic profiles and
assess their interplay with the CMS classification of
CRC. We also analysed the composition and func-
tional orientation of immune and stromal populations
of the tumour microenvironment, as well as specificNA 
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Fig. 2. Clinical and molecular characteristics of colorectal cancer (CRC) patients according to immune subtypes. Bar plots showing the
proportion of gender, stage, primary tumour localisation, histology, KRAS, NRAS, BRAF, APC, and TP53 mutations, hypermutated
phenotype, microsatellite instability and CpG island methylator phenotype (CIMP) in immune subtypes C1 (wound healing), C2 (IFN-g
dominant), C3 (inflammatory), C4 (lymphocyte depleted ) and C6 (TGF-b dominant). The number of patients with specific clinical infor-
mation for each immune subtype is detailed below the bar plot.
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population.2. Material and methods
2.1. Study population and datasets
The study population included all CRC patients from
TCGA [13] (NZ 625) with available information on ISs
[12](N Z 597). Clinical and molecular information,
CMS classification and transcriptomic profiles were
obtained from different public data platforms (see
Supplementary Material and Methods). Main charac-
teristics of the study population are summarised in
Supplementary Tables 1 and 2).2.2. Clinical and molecular data analyses
Associations of categorical variables and CRC subtypes
were assessed by using the Fisher’s exact test. Overall
Survival (OS) was estimated according to the Kaplan-
Meier method [14]. Cox proportional-hazard univariate
and multivariate analyses were also conducted,
including relevant known clinical and pathological
prognostic factors as well as the IS and CMS classifi-
cations (see Supplementary Material and Methods).2.3. Immune cell population analysis
Differences in the fraction of immune cell types, M1/M2
ratio, B-cell receptor and TCR diversity among ISs were
performedbyusing theWilcoxon signed-rank test. Immune
and stromal cell populations were estimated by using
microenviroment cell populations (MCP)-counter [11].
Statistical differences between ISs were evaluated using the
Student’s t-test. ComplexHeatmap R package [15] and Z-
score values obtained from all samples were used to
generate immune population and IS heatmaps (see Sup-
plementary Material and Methods).2.4. Differential expression and gene set enrichment
analysis
Differential expression analysis (DEG) between wound
healing and IFN-g dominant ISs was performed using
Bioconductor’s DESeq2 package [16]. Genes with FDR
<0.05 were selected as differentially expressed between
both subtypes. Gene set enrichment analysis (GSEA)
was computed with ssGSEA algorithm implemented in
Bioconductor’s GSVA R package [17], Hallmarks and
KEGG gene sets (details of differentially expressed
genes (DEG) and GSEA included in Supplementary
Material and Methods).2.5. Analysis of immune modulator genes
Only samples with RNA-seq data available were used
for immune modulator gene expression analysis
(NZ 590). Kruskal-Wallis or Wilcoxon signed-rank test
was performed depending on the number of ISs
considered in each analysis (see Supplementary Material
and Methods).3. Results
3.1. Immune subtype distribution in the global colorectal
cancer population by consensus molecular subtype
First, we assessed the distribution of ISs in the global
CRC population (N Z 573), and we found that the 2
predominant ISs were the C1 wound healing subtype,
identified in 459 samples (77%) and the C2 IFN-g domi-
nant subtype, present in 103 samples (17%). Other ISs
were far less commonly encountered, such as the C3 in-
flammatory (18 samples, 3%), C4 lymphocyte depleted (13
samples, 2%) and C6 TGF-b dominant (4 samples, 0.7%)
subtypes. Of note, no CRC sample belonged to the C5
immunologically quiet IS (Supplementary Table 1).
Next, we explored the distribution of ISs by CMS to
assess the interplayof bothmolecular classifications (Fig. 1,
Supplementary Tables 3 and 4). The 2 main CRC ISs, C1
and C2, were present in all CMS groups but their relative
distribution differed byCMS. Indeed, theC1woundhealing
IS was particularly dominant in CMS2 (91%) but far less
common in CMS1 (46%) tumours, whereas the proportion
of C1 in CMS3 and CMS4 tumours was intermediate
(77e78%).On the contrary, theC2 IFN-g dominantwas the
most common IS observed in CMS1 (53%) and was under-
represented inCMS2 (8%),whereas the proportion ofC2 in
CMS3 and CMS4 was slightly higher (11e13%). Other ISs
were barely present in CMS1 and CMS2. The immuno-
logical landscape of CMS3 and CMS4 was more diverse:
theywere enriched in theC3 inflammatory subtype (7% and
6%, respectively), as compared with CMS1/2, CMS3 had
the highest representation of the C4 lymphocyte depleted
subtype (4%), and all 3 cases ofTGF-b dominant phenotype
belonged to the CMS4 subgroup (2.3%). Distribution of
CMSby ISs is detailed inFig. 1 andSupplementaryTable 4.
3.2. Clinical and molecular features of colorectal cancer
by IS
The main clinical and molecular characteristics by IS in
the global CRC population are depicted in Fig. 2 and
detailed in Supplementary Table 4, and analysed by
CMS in Supplementary Figs. S2e5 and Supplementary
Tables 5e8. C2 IFN-g dominant, C4 lymphocyte depleted
and C6 TGF-b dominant ISs were enriched in tumours
located in the right colon, whereas C1 wound healing and
C3 inflammatory ISs were frequently encountered in left-
B. Soldevilla et al. / European Journal of Cancer 123 (2019) 118e129 123sided tumours. No significant associations were
observed with gender or tumour stage.
All ISs presented a similar proportion of KRAS
mutations, except for the TGF-b dominant IS, where no
KRAS mutations were identified. BRAF mutations
were more commonly observed in IFN-g dominant
(25%), lymphocyte depleted (17%) and TGF-b dominant
(33%) subtypes, although these figures are not particu-
larly accurate in these last subgroups because of the
small sample size. MSI, CpG island methylator pheno-
type, and hypermutated phenotypes were consistently
more common in the IFN-g dominant subtype. Most
frequent genetic alterations encountered in CRC are
provided by IS in Supplementary Table 9. Distribution
of clinical and molecular characteristics by CMS is
consistent with the previous data [7] (Supplementary
Fig. S1 and Supplementary Table 3).
3.3. Prognostic impact of immune subtypes in colorectal
cancer
The immune phenotype had a major influence on pa-
tient’s prognosis, although its impact on CRC patients
significantly differed from the overall TCGA, which
included over 30 different solid tumour types [12]
(Fig. 3A). Indeed, in our CRC study cohort, patients
with TGF-b dominant and wound healing ISs showed
better prognosis (5-year OS of 100% and 65%, respec-
tively), whereas IFN-g dominant and inflammatory ISs
were associated with the worst outcome (5-year OS of
49% and 23%, respectively) (C2 vs C1, HR 1.59, P ZFig. 3. Impact of immune subtypes on survival of colorectal cancer pati
TCGA solid tumour population (NZ 9074). B) Overall survival by im
risk at the corresponding time point and survival rates at five years in e0.004; C3 vs C1, HR 2.77, P Z 0.02) (Fig. 3B,
Supplementary Table 10). Similar trends were observed
when analysed within each CMS (Supplementary
Fig. S6 and Supplementary Table 10).
Cox multivariate analysis showed that ISs were
significantly associated with survival, independent of
other well-established prognostic factors in CRC such as
age, stage at diagnosis or primary tumour site
(Supplementary Table 11), and showed that the immune
phenotype had a significantly greater influence on OS
than CMS.3.4. Immune subtypes of colorectal cancer show distinct
immune and stromal cell population patterns
Different patterns for immune and stromal cell
population abundance were found among ISs in CRC
patients. The most relevant differences were identified
between the two major subtypes (C1 and C2). IFN-g
dominant tumours presented higher levels of CD8, CD4,
follicular helper T cells and M1 macrophages. High
levels of NK cells, M2 macrophages, M1/M2 ratio and
neutrophils were also found in this subtype (Fig. 4). No
differences were found in endothelial cells and fibro-
blasts abundance between these two groups, although
the proportion of these populations was strikingly high
in the TGF-b subtype (Fig. 4B). When analysed by CMS
group, similar differences were observed in the CMS1
group (Supplementary Fig. S7), but these were diluted in
the CMS2-4 groups (Supplementary Figs. 8e10).ents. A) Overall survival (OS) by immune subtypes in the overall
mune subtypes in the TCGA CRC cohort (NZ 572). Patients at
ach subtype are provided. P-value was calculated by log-rank test.
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****P < 0.0001 using Wilcoxon signed-rank test. B) MCP counter heatmap showing the estimated abundance of several immune and
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immunomodulatory genes
Next, we examined gene expression, amplification or
deletion of a large set of immunomodulators (IMs)
genes across ISs. Upregulation of several IMs was found
in the IFN-g dominant subtype, such as CD80 (FDR Z
1.69E-12), CD28 (FDR Z 5.20-9), CD274 (PDL-1)
(FDR Z 6.82E-23), CXCL10 (FDR Z 1.83E-24),
LAG3 (FDRZ 6.94E-21), ICAM1 (FDRZ 1.41E-11),
HLA-DQA1 (FDR Z 3.84E-16), HLA-DRA (FDR Z
3.38E-17), IDO1 (FDR Z 8.44-20) and GZMA (FDR
Z 3.34E-18) (Fig. 5A and Supplementary Fig. 12).
Immune inhibitors with the greatest differences between
subtypes included PDL-1, PD-1, CTLA-4, IDO1 or
LAG3 and were most highly expressed in the IFN-g
dominant subtype (Fig. 5B). Significant differences
observed between the 2 major immune phenotypes (C1and C2) were maintained within each CMS
(Supplementary Fig. 11). Copy-number variations
affected multiple IMs and both amplifications and de-
letions were frequently found in the wound healing IS,
whereas other ISs showed fewer alterations (Fig. 5A).
Thus, SLAMF4, TNFSF4, CX3CL1, IL10, IL2,
ENDRB, CD40, IDO1 and HMGb1 genes were most
frequently amplified, whereas VTCN1, CD276 (PDL-1),
IL4, IL13, TNGRS-F18, TNGRS-F4, TNGRS-F9,
TNGRS-14, and ADORA2A were most frequently
deleted in C1 IS.
We also found that both tumour mutational
burden and antigen-specific TCR repertoires, which
determine the robustness of the antitumour response,
were enriched in IFN-g dominant (N Z 56) compared
with wound healing (NZ 258) IS. A trend was observed
in BCR diversity between these main ISs (Fig. 5 and
Supplementary Fig. S11).
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Fig. 5. Regulation of immunomodulators. A) mRNA expression (median z-score), amplification frequency (difference between the observed
versus expected fraction of samples in which an IM is amplified) and deletion frequency (difference between the observed versus expected
fraction of samples in which an IM is deleted) for 75 immunomodulator genes by immune subtype. B) Distribution of expression levels for
immune checkpoints (log2-transformed), tumour mutational burden (TMB), BCR and TCR diversity (logþ1 transformed) by immune
subtypes: C1 (wound healing), C2 (IFN-g dominant), C3 (inflammatory), C4 (lymphocyte depleted ) and C6 (TGF-b dominant). The number
of patients with gene expression data for each immune subtype is detailed below the bar plot. P-value was calculated by Kruskal-Wallis
test for immune checkpoints and by Wilcoxon singed-rank test for TMB, BCR and TCR analysis.
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wound healing and IFN-g dominant subtypes identify key
genes and pathways of potential diagnostic or therapeutic
relevance in CRC
A total of 3150 and 1362 differentially expressed genes
achieved statistical significance (FDR < 0.05) between
wound healing and IFN-g dominant subtypes when we
analysed all and CMS1 CRC patients, respectively.
The expression profile of an important number of
genes was specific to each CMS, but 21 genes were
consistently found to be differentially expressed in
all analysis performed (Fig. 6A and Supplementary
Table 13).
GSEA pathway analysis showed that the wound
healing subtype was enriched in metabolic pathways,
and had greater activation of WNT and hedgehog sig-
nalling (Fig. 6B). In contrast, the IFN-g dominantsubtype presented greater activation of pathways related
to the immune system, apoptosis and DNA repair, as
well as mTOR signalling and oxidative phosphorylation
(Fig. 6B and Supplementary Table 14). Pathway ana-
lyses by IS within each CMS are provided in
Supplementary Fig. 12 and Supplementary Tables
15e18.4. Discussion
An increasing body of evidence supports the major
role that tumour microenvironment and, in particular,
the immune system play in cancer fate. An improved
understanding of the immune landscape of cancer is
therefore critical to refine current immunotherapeutic
strategies that have revolutionised cancer care, but
are still ineffective in a great proportion of CRC
Fig. 6. Differential expression of genes and pathways between wound healing and IFN-g dominant immune subtypes in CRCcolorectal
cancer patients. A) An histogram displaying the differential gene expression profile of wound healing versus IFN-g dominant immune
subtypes by CMS. The number of genes with significantly different expression levels (FDR<0.05) were provided for all (NZ 507), CMS1
(N Z 71), CMS2 (N Z 206), CMS3 (N Z 62) and CMS4 (N Z 120) colorectal patients. B) Heatmap showing the gene set mRNA
enrichment analysis (ssGSEA) of signatures (median z-scores) of special interest in CRC in the 2 predominant immune subtypes, wound
healing and IFN-g dominant.
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cancer immune classification that encompasses nearly
all human malignancies, and consists of 6 (ISs with
distinct immunogenomic features and clinical out-
comes [12]. However, distribution of these ISs sub-
stantially differed across the 33 solid tumours
included, and their association with patients’ prognosis
was also dependent on tumour type. In the present
study, we specifically characterised the ISs in the
TCGA cohort of CRC patients, and assessed their
interplay with the most robust molecular classification
reported to date in CRC, the CMS classification [7]. In
our study, we show that only 5 of the 6 ISs are present
in CRC patients, with 2 predominant ones (the C1
wound healing subtype [77%] and the C2 IFN-g domi-
nant subtype [17%]), and demonstrate significant het-
erogeneity of immune phenotype distribution among
CMS subgroups. Importantly, we observed that the
immune phenotype has greater influence in survival
than the CMS classification. These findings may have
relevant implications in terms of prognosis stratifica-
tion and prediction of response to therapy, and suggest
the immune phenotype may allow a more accurate
classification of patients to assist clinicians in person-
alised patient care.Indeed, the C1 wound healing IS was particularly
dominant in CMS2 (91%) but far less common in CMS1
(46%) tumours, and the C2 IFN-g dominant was the
most common IS observed in CMS1 tumours (53%) and
was under-represented in CMS2 tumours (8%). Other
ISs were barely present in CMS1 and CMS2 tumours,
whereas the immunological landscape of CMS3 and
CMS4 was more diverse: they had some representation
of the C3 inflammatory (7% and 6%, respectively) and
C4 lymphocyte depleted (4.3% and 1.5%, respectively)
subtypes, and all 3 cases with TGF-b dominant pheno-
type belonged to the CMS4 subgroup (2.3%). Of note,
ISs were significantly associated with survival in CRC
patients, independent of other well established prog-
nostic factors (age, stage at diagnosis or primary tumour
site), whereas the CMS lost statistical significance in the
Cox multivariate analysis.
These observations are consistent with the fact that
clinical and molecular features enriched in CMS1 were
also over-represented in IFN-g dominant patients, and
the strong immune activation observed in CMS1 [7,8]
could be explained by the enrichment of IFN-g
dominant tumours in this CMS. To date, CMS1 (MSI-
like immune) patients have been postulated to be the
most likely to benefit from immunotherapy, as this
B. Soldevilla et al. / European Journal of Cancer 123 (2019) 118e129 127subtype includes most MSI/highly mutated tumours
[18,19]. Nevertheless, not all CMS1 are MSI and other
CMS subgroups (i.e CMS3) also include a significant
proportion of MSI tumours. This is relevant as MSI is
the biomarker used in pivotal studies that demon-
strated the clinical efficacy of checkpoint inhibitors in
CRC, and the only available biomarker in standard
clinical practice to identify immunogenic CRC [11].
Moreover, our results reported that the immune
landscape of CMS1 is diverse and this may potentially
impact response to therapy. Given the fact that IFN-g
dominant tumours presented a strong immune activa-
tion (high proportion of CD8, follicular helper T cells
and M1 macrophages, as well as Tregs, M2 macro-
phages, dendritic cells and neutrophils) and upregu-
lation of several immune regulatory genes (PD-1/PD-
L1, CTLA-4, IDO1 and LAG3) potentially involved in
immune escape mechanisms, it is reasonable to assume
that the IFN-g dominant IS may be accountable for
the susceptibility of CMS1 tumours to immune
checkpoint inhibition, whereas CMS1 tumours of the
wound healing subtype may likely be more resistant to
these agents and would require other therapeutic ap-
proaches. In addition, IFN-g dominant tumours
belonging to CMS2-4 subgroups could also potentially
benefit of immune checkpointetargeted therapy. This
is particularly relevant as MSI tumours only represent
a small proportion of patients with advanced CRC
(w5%), and despite the unquestionable success of
immunotherapy in this subgroup of patients, still a
significant proportion of MSI tumours (40e60%) do
not respond to immune checkpoint inhibitors for yet
unexplored biological grounds. On the contrary, a
subset of MSS tumours also show increased expression
of immune genes, indicating that other factors also
determine immune contexture and clinical outcomes
[20,21]. The IS classification could be therefore a new
valuable tool to aid in the selection of patients for
immune therapy. Like CMS1, CMS4 tumours are also
characterised by a prominent immune activation [7,8],
and it has been postulated that this CMS subgroup
could also benefit from immune checkpoint inhibitors
but most likely in combination with other treatment
strategies [8].The most common ISs in CMS4 tumours
were the wound healing (78%) followed by the IFN-g
dominant (13%) subtypes, but, together with CMS3,
these tumours were also relatively enriched in the in-
flammatory subtype (6%). The inflammatory pheno-
type has been associated with cancer progression by
multiple mechanisms and, consistently, these samples
were part of the CMS4 group, the CMS with the
poorest prognosis. It is also important to highlight
that all TGF-b dominant tumours belonged to the
CMS4 subtype, although the number of patients was
very low. TGF-b phenotype in CRC has recently been
associated with a reduced cytotoxic T-cell responseagainst tumour cells and resistance to PD-1 blockade,
being a primary mechanism of immune evasion [22].
Another relevant finding of our study was that the
prognostic impact of ISs in CRC was substantially
different from that reported for the global TCGA [12].
Indeed, CRC patients with the TGF-b dominant and
wound healing ISs showed better prognosis (5-year OS:
100% and 65%, respectively), whereas IFN-g dominant
and inflammatory subtypes were associated with the
worst outcome (5-year OS: 49% and 23%, respectively).
This in sharp contrast with survival rates by IS reported
for the overall solid tumour population, where the in-
flammatory subtype had the best prognosis, and the
lymphocyte depleted and TGF-b dominant were the ISs
associated with the worst survival [12]. On the other
hand, the excellent prognosis of TGF-b dominant tu-
mours was certainly unexpected, despite they all
belonged to the CMS4 group, and particularly consid-
ering TGF-b signalling in stromal cells is a defining
feature of poor prognosis CRC subtypes [23]. However,
only 4 CRC samples (0.7%) were TGF-b dominant,
which preclude firm conclusions to be drawn.
Our observations may be partially conditioned by
some caveats inherent to the use of TCGA data. First is
the fact that for most tumour types, a tumour cell
component >50% was required for study entry; this
introduces a significant bias as the epithelial cell
component is likely over-represented. In addition, sur-
vival rates and patient follow-up substantially differed
across tumour types, antitumour therapy is presumably
very heterogeneous, and its impact on clinical outcomes
is disregarded. Finally, it should be pointed out that the
IS classification was developed in a large but very het-
erogeneous cancer population, which may dilute
distinct, potentially relevant tumour-specific tran-
scriptomic profiles. Thus, further refinement of this
classification specifically adjusted for CRC is certainly
warranted.
In summary, in line with the changing treatment
paradigm, that is shifting from the traditional one pre-
dominantly focused on targeting the epithelial
compartment, to the development of more integrated
approaches targeting tumour microenvironment, in-
depth study of the immune landscape of tumours pro-
vides very valuable information for cancer management.
In the present study, we have characterised the recently
described pan-cancer IS classification in a large cohort
of CRC patients, demonstrating distinct clinical and
biological implications of ISs in this cancer type. We
have also identified substantial heterogeneity in the
distribution of ISs by CMS subgroups, and demonstrate
that ISs have greater ability to stratify prognosis of
CRC patients than the CMS classification. Profound
biological differences observed among ISs are expected
to translate into heterogeneous drug responses, both to
conventional cytotoxic drugs and to alternative treat-
ment strategies targeting the tumour ecosystem,
B. Soldevilla et al. / European Journal of Cancer 123 (2019) 118e129128including immunotherapy. We believe these results are
highly relevant and should be taken into account for the
design of future therapeutic strategies that may eventu-
ally improve the fate of CRC patients.5. Conclusions
Cancer is the consequence of a complex interplay be-
tween tumour cells and their microenvironment.
Recently, a new global transcriptomic immune classifi-
cation of solid tumours has identified six ISs (C1eC6)
which spans across traditional cancer classifications
based on anatomical site of origin and suggests that
certain therapeutic approaches may be considered
regardless of tumour location or histology. However,
individual tumour types varied substantially in their
proportion of ISs and in their prognostic impact. Thus,
we have characterised, from a clinical and molecular
perspective, the ISs in a large cohort of CRC patients,
and we have assessed their interplay with the most ac-
curate classification system in CRC, CMSs. CMSs show
substantial heterogeneity in the distribution of ISs with
relevant clinical and biological implications and a sig-
nificant impact on patients’ survival. Profound biolog-
ical differences observed among ISs could be translated
into heterogeneous drug responses to conventional
cytotoxic drugs and to novel strategies such as immu-
notherapies. These results are highly relevant and should
be taken into account for the design of future thera-
peutic strategies that may eventually improve the fate of
CRC patients.Conflict of interest statement
The authors declare no competing interests related to
the published work.Acknowledgement
This work was funded by projects DTS15/00157,
PI16/01827 and CIBER-ONC CB16/12/00442 from the
Instituto de Salud Carlos III (Ministry of Economy,
Industry and Competitiveness, Spain) and cofunded by
the European Regional Development Fund (ERDF,
European Union), and approved by the Ethics Com-
mittee or our Institution. BS is funded by AECC
(Spain). MCR is funded by Instituto de Salud Carlos III
and SEOM (Spain) CCP and BRC are funded by CAM
(Programa de Empleo Juvenil (YEI)).
Appendix A. Supplementary data
Supplementary data to this article can be found online
at https://doi.org/10.1016/j.ejca.2019.09.008.References
[1] Budinska E, Popovici V, Tejpar S, D’Ario G, Lapique N,
Sikora KO, et al. Gene expression patterns unveil a new level of
molecular heterogeneity in colorectal cancer. J Pathol 2013;
231(1):63e76.
[2] Melo FDSE, Wang X, Jansen M, Fessler E, Trinh A, de
Rooij LP, et al. Poor-prognosis colon cancer is defined by a
molecularly distinct subtype and develops from serrated precursor
lesions. Nat Med 2013;19(5):614e8.
[3] Marisa L, de Reynie`s A, Duval A, Selves J, Gaub MP, Vescovo L,
et al. Gene expression classification of colon cancer into molecular
subtypes: characterization, validation, and prognostic value.
PLOS Med 2013;10(5):e1001453.
[4] Roepman P, Schlicker A, Tabernero J, Majewski I, Tian S,
Moreno V, et al. Colorectal cancer intrinsic subtypes predict
chemotherapy benefit, deficient mismatch repair and epithelial-to-
mesenchymal transition. Int J Cancer 2014;134(3):552e62.
[5] Sadanandam A, Lyssiotis CA, Homicsko K, Collisson EA,
Gibb WJ, Wullschleger S, et al. A colorectal cancer classification
system that associates cellular phenotype and responses to ther-
apy. Nat Med 2013;19(5):619e25.
[6] Schlicker A, Beran G, Chresta CM, McWalter G, Pritchard A,
Weston S, et al. Subtypes of primary colorectal tumors correlate
with response to targeted treatment in colorectal cell lines. BMC
Med Genomics 2012;5:66.
[7] Guinney J, Dienstmann R, Wang X, de Reynie`s A, Schlicker A,
Soneson C, et al. The consensus molecular subtypes of colorectal
cancer. Nat Med 2015;21(11):1350e6.
[8] Sveen A, Bruun J, Eide PW, Eilertsen IA, Ramirez L,
Muruma¨gi A, et al. Colorectal cancer consensus molecular sub-
types translated to preclinical models uncover potentially target-
able cancer cell dependencies. Clin Cancer Res Off J Am Assoc
Cancer Res 2018;24(4):794e806.
[9] Lenz H-J, Ou F-S, Venook AP, Hochster HS, Niedzwiecki D,
Goldberg RM, et al. Impact of consensus molecular subtyping
(CMS) on overall survival (OS) and progression free survival
(PFS) in patients (pts) with metastatic colorectal cancer (mCRC):
analysis of CALGB/SWOG 80405 (Alliance). J Clin Oncol 2017;
35(15_suppl):3511.
[10] Stintzing S, Wirapati P, Lenz H-J, Neureiter D, Weikersthal LF,
Decker T, et al. Consensus molecular subgroups (CMS) of colo-
rectal cancer (CRC) and first-line efficacy of FOLFIRI plus
cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial. J
Clin Oncol 2017;35(15_suppl):3510.
[11] Becht E, de Reynie`s A, Giraldo NA, Pilati C, Buttard B,
Lacroix L, et al. Immune and stromal classification of colorectal
cancer is associated with molecular subtypes and relevant for
precision immunotherapy. Clin Cancer Res 2016;22(16):4057e66.
[12] Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou
Yang TH, et al. The immune landscape of cancer. Immunity 2018;
48(4):812e830.e14.
[13] The Cancer Genome Atlas Network. Comprehensive molecular
characterization of human colon and rectal cancer. Nature 2012;
487(7407):330e7.
[14] Kaplan EL, Meier P. Nonparametric estimation from incomplete
observations. J Am Stat Assoc 1958;53(282):457e81.
[15] Gu Z, Eils R, Schlesner M. Complex heatmaps reveal patterns
and correlations in multidimensional genomic data. Bioinforma
Oxf Engl 2016;32(18):2847e9.
[16] Love MI, Huber W, Anders S. Moderated estimation of fold
change and dispersion for RNA-seq data with DESeq2. Genome
Biol 2014;15(12):550.
[17] Ha¨nzelmann S, Castelo R, Guinney J. GSVA: gene set variation
analysis for microarray and RNA-Seq data. BMC Bioinformatics
2013;14(1):7.
B. Soldevilla et al. / European Journal of Cancer 123 (2019) 118e129 129[18] Le DT, Durham JN, Smith KN, Wang H, Bartlett BR,
Aulakh LK, et al. Mismatch repair deficiency predicts response of
solid tumors to PD-1 blockade. Science 2017;357(6349):409e13.
[19] Gelsomino F, Barbolini M, Spallanzani A, Pugliese G, Cascinu S.
The evolving role of microsatellite instability in colorectal cancer:
a review. Cancer Treat Rev 2016;51:19e26.
[20] Galon J, Page`s F, Marincola FM, Angell HK, Thurin M, Lugli A,
et al. Cancer classification using the immunoscore: a worldwide
task force. J Transl Med 2012;10:205.
[21] Mlecnik B, Bindea G, Angell HK, Maby P, Angelova M,
Tougeron D, et al. Integrative analyses of colorectal cancer showimmunoscore is a stronger predictor of patient survival than mi-
crosatellite instability. Immunity 2016;44(3):698e711.
[22] Tauriello DVF, Palomo-Ponce S, Stork D, Berenguer-Llergo A,
Badia-Ramentol J, Iglesias M, et al. TGFb drives immune evasion
in genetically reconstituted colon cancer metastasis. Nature 2018;
554(7693):538e43.
[23] Calon A, Lonardo E, Berenguer-Llergo A, Espinet E, Hernando-
Momblona X, Iglesias M, et al. Stromal gene expression defines
poor-prognosis subtypes in colorectal cancer. Nat Genet 2015;
47(4):320e9.
